Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Prime Medicine, Inc.PRME · Entity 5281 | 10% owner | June 30, 2025 | July 01, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Prime Medicine, Inc.
Report date June 30, 2025 · Filed July 01, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,240,945 |
Reported balance
After 2025-06-30 transaction · row 1
1 source rowRow 1 · 2025-06-30 · Purchase · Acquired 21,000 · Balance 20,240,945 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. F2: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025.
F2: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2025 Filed Jul 1, 2025 20:03 UTC | Prime Medicine, Inc. PRME · Entity 5281 | PurchaseCommon Stock | 21,000 | $2.52 | $52,829.70 |
DisclosureSEC source: 0001628280-25-033754 · wk-form4_1751400224.xml · nonDerivative · entry 1 Liu David R. · CIK 0001664439 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,240,945 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. F2 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 23, 2025 Filed Jun 23, 2025 20:33 UTC | Prime Medicine, Inc. PRME · Entity 5281 | PurchaseCommon Stock | 21,000 | $2.16 | $45,402.00 |
DisclosureSEC source: 0001628280-25-032626 · wk-form4_1750710792.xml · nonDerivative · entry 1 Liu David R. · CIK 0001664439 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,219,945 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. F2 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.06 to $2.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2025 Filed Jun 16, 2025 21:14 UTC | Prime Medicine, Inc. PRME · Entity 5281 | PurchaseCommon Stock | 21,000 | $1.49 | $31,195.50 |
DisclosureSEC source: 0001628280-25-031637 · wk-form4_1750108485.xml · nonDerivative · entry 1 Liu David R. · CIK 0001664439 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,198,945 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. F2 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.46 to $1.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 20:49 UTC | Prime Medicine, Inc. PRME · Entity 5281 | PurchaseCommon Stock | 21,000 | $1.60 | $33,589.50 |
DisclosureSEC source: 0001628280-25-031045 · wk-form4_1749761367.xml · nonDerivative · entry 1 Liu David R. · CIK 0001664439 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,177,945 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. F2 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 21, 2023 Filed Jul 26, 2023 00:15 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001894562-23-000030 · wf-form4_169033049649105.xml · nonDerivative · entry 1 Liu David R. · CIK 0001664439 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,156,945 Read SEC document |
| July 21, 2023 Filed Jul 26, 2023 12:29 UTC Amendment | Prime Medicine, Inc. PRME · Entity 5281 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001894562-23-000032 · wf-form4a_169037455528840.xml · nonDerivative · entry 1 Liu David R. · CIK 0001664439 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,156,945 F1 · kind: This Form 4 Amendment is being filed solely to report the disposition as a bona fide gift by the Reporting Person of the Issuer's common stock to a 501(c)(3) charitable organization for no consideration. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 00:00 UTC | Prime Medicine, Inc. PRME · Entity 5281 | ConversionSeries A Convertible Preferred Stock · Derivative | 1,000,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-027123 · wf-form4_166682883819559.xml · derivative · entry 2 Liu David R. · CIK 0001664439 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 321,665 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 00:00 UTC | Prime Medicine, Inc. PRME · Entity 5281 | ConversionCommon Stock | 321,665 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-027123 · wf-form4_166682883819559.xml · nonDerivative · entry 1 Liu David R. · CIK 0001664439 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,156,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.